Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors
The primary objective is to determine the safety and maximum tolerated dose (MTD) of Genasense administered as a 2-hour intravenous infusion once weekly (Part 1) and twice weekly (Part 2) to patients with solid tumors.
Solid Tumors
DRUG: Oblimersen (Genasense)|DRUG: Oblimersen (Genasense)
Maximum tolerated dose (MTD) of Genasense administered as a 2-hour IV infusion once a week (Part 1) and twice a week (Part 2) to patients with solid tumors, One year
Pharmacokinetics (Part 1 and Part 2); pharmacodynamics (Part 2), During treatment phase
The primary objective is to determine the safety and maximum tolerated dose (MTD) of Genasense administered as a 2-hour intravenous infusion once weekly (Part 1) and twice weekly (Part 2) to patients with solid tumors.